Clinigen Group (CLIGF) Stock Price, News & Analysis

Company Overview

Clinigen Group is a United Kingdom-based pharmaceutical services company focused on providing access to medicines that are difficult to source, require specialist distribution, or are not yet widely available in particular markets. Its activities have included supplying specialty and critical-care medicines to hospitals, pharmacies, pharmaceutical companies, and other healthcare providers.

The company has also provided clinical-trial services, including the sourcing, packaging, labeling, storage, and distribution of investigational medicines. Through its global access activities, Clinigen has helped pharmaceutical and biotechnology companies make medicines available in countries where products may not yet have full commercial approval or established distribution channels.

Clinigen was established in 2010 through the combination of businesses involved in the supply of unlicensed medicines and clinical-trial products. It expanded its operations internationally and was formerly listed on the London Stock Exchange. The company was acquired by a consortium led by Triton Partners in 2022 and subsequently delisted. Clinigen’s operations have served customers across the United Kingdom, Europe, North America, Asia-Pacific, and other international markets.

Key Stats

• Today's Range: $8.02 to $8.02
• 50-Day Range: $8.02 to $8.02
• 52-Week Range: $8.02 to $11.56
• Volume: N/A
• Average Volume: 8,620 shs
• Market Capitalization: $1.07 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/11/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Private households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CLIGF
• Previous Symbol: NASDAQ:CLIGF
• CIK: N/A
• Web: www.clinigengroup.com
• Phone: 44-12-8349-5010
• Fax: 01283 495011
• Employees: 1,069
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $704.71 million
• Price / Sales: 1.51
• Cash Flow: $1.43 per share
• Price / Cash Flow: 5.60
• Book Value: $4.52 per share
• Price / Book: 1.77

Miscellaneous

• Outstanding Shares: 133,030,000
• Free Float: N/A
• Market Cap: $1.07 billion
• Optionable: Not Optionable
• Beta: 0.49